Navigation Links
InterMune Announces Start of Phase 1b Trial of ITMN-191
Date:9/26/2007

F) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1a, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 30, 2007 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulat
'/>"/>

SOURCE InterMune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting
2. InterMune Presents Research on ITMN-191 in Hepatitis C at EASL Annual Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015 PAREXEL International Corporation (NASDAQ: PRXL ) ... Healthcare Conference on Monday, May 18, 2015, in New York ... Financial Officer will be making a presentation on PAREXEL and ... live webcast of the presentation will be available through the ... the Upcoming Events portion of the main page, and a ...
(Date:5/4/2015)... -- Impax Laboratories, Inc. (NASDAQ: IPXL ) announced that ...  Donna M. Hughes, as Senior Vice President, Human Resources ... President, Chief Compliance Officer. Both Ms. Hughes and Ms. ... Officer, Fred Wilkinson . "We are ... team," said Fred Wilkinson , President and Chief ...
(Date:5/4/2015)... , May 4, 2015 Rogne Bioscience, ... psoriasis, today announced that preclinical and mechanism of action ... the Society of Investigative Dermatology (SID) Annual Meeting being ... Atlanta, Georgia . Logo - ... the development of RON2315, a novel, low MW (<1700 ...
Breaking Medicine Technology:PAREXEL International to Present at UBS Healthcare Conference 2Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 2Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 3Rogne Bioscience to Present Data from Topical Biologic Psoriasis Program at Upcoming SID Annual Meeting 2015 2
... , , SAN FRANCISCO, Aug. 21 ... first annual "Bridge to Hope," an all-day music festival set to be held ... from 11:00 a.m. to 7:00 p.m. The event will also include an ... selection of gourmet fare from a number of the city,s favorite eateries. , ...
... , , , ... Bay(R) Pharmaceuticals , Inc. (NYSE-Amex: NBY ), a ... prevention of a wide range of bacterial, viral, and fungal infections, ... on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA. ...
Cached Medicine Technology:Tickets On Sale Now: 'Bridge to Hope' All-Day Music Festival to Feature Top Artists, Gourmet Food, Art Show, Saturday, September 26th at Fort Mason's Great Meadow 2Tickets On Sale Now: 'Bridge to Hope' All-Day Music Festival to Feature Top Artists, Gourmet Food, Art Show, Saturday, September 26th at Fort Mason's Great Meadow 3Tickets On Sale Now: 'Bridge to Hope' All-Day Music Festival to Feature Top Artists, Gourmet Food, Art Show, Saturday, September 26th at Fort Mason's Great Meadow 4Tickets On Sale Now: 'Bridge to Hope' All-Day Music Festival to Feature Top Artists, Gourmet Food, Art Show, Saturday, September 26th at Fort Mason's Great Meadow 5NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting 2NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting 3
(Date:5/4/2015)... Friday afternoon at A Forever Recovery, a result-driven substance ... staff gather in the common room to celebrate the ... gain encouragement and inspiration in their continuing effort to ... patients who have completed their recovery programs come to ... a bit about their journey with the audience. Some ...
(Date:5/4/2015)... The American Council of Engineering Companies ... Stanley Consultants , to the Institute of ... three-year term. , ACEC co-established ISI with the American ... Civil Engineers (ASCE). A non-profit group, ISI developed ... called Envision. Launched in 2012, the Envision rating system ...
(Date:5/4/2015)... May 04, 2015 Malibu Biotech ... antiseptic breath spray. KissSafe™ is the first personal ... safer experience while adding fresh breath appeal. KissSafe™ ... effectively kills germs in the mouth and oral ... contains ingredients that possess additional wellness benefits. KissSafe’s ...
(Date:5/4/2015)... May 04, 2015 Leonardo J. Lozada, ... chief physician executive, and William C. Daniel, M.D., Saint ... accepted personal invitations from the Secretary of the Air ... (NSF) at the Air War College, Maxwell Air Force ... influential citizens to senior U.S. and international officers and ...
(Date:5/4/2015)... The University of California, Davis and ... initiative at UC Davis School of Medicine dedicated ... to advancing Latino health. , The program, called ... to Be Physicians, (“Prep Médico” for short) is ... and internship opportunities, a residential program, intensive language ...
Breaking Medicine News(10 mins):Health News:A Forever Recovery Celebrates New Victories in Overcoming Addiction With Weekly Graduation 2Health News:Thomopulos Appointed to Institute for Sustainable Infrastructure Board 2Health News:80 Million Germs from Kissing - Introducing KissSafe™ 2Health News:Saint Luke’s Health System Leadership Selected to Attend National Security Forum 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 3Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 4Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 5
... how we put the brakes on a racing heartbeat. ... Chicago explain in the May 11 issue of Circulation Research ... the rapid beating of the heart's "fight-or-flight" reaction to adrenaline. ... is responsible for setting the pace of the beating heart, ...
... The central government is aiming for 100 percent registration of ... Death Act 1969 that would simplify the process, an ... serious issue as this helps in maintaining a record for ... the birth registration record is 64 percent as some of ...
... 100 percent registration of births by 2010 by amending the ... simplify the process, an official said Friday. ,'Registration ... maintaining a record for a person for his or her ... percent as some of the states have still not implemented ...
... a single sphere in the US they would like to ... is the cooked chickens market. ,The U.S. ... to familiarize the U.S. market with its cooked chickens." ... about such common practices among Chinese farmers, like flooding crops ...
... of motor disorders: stiffness, slowness, tremors, difficulties walking and ... other symptoms with narcolepsy, a sleep disorder characterized by ... and general sleep disorder. ,Now a team ... why the two disorders share something in common: ...
... receiver Robert Sillen, hired to improve healthcare for state ... his jurisdiction. ,According to Sillen the 50-page ... and protect California communities from diseases carried by inmates ... says, taxpayers will get more for their dollar from ...
Cached Medicine News:Health News:Slowing the Racing Heart 2Health News:Government to Amend Birth Registration Act 2Health News:Government to Amend Birth Registration Act 2Health News:China Eyeing US Cooked Chickens Market 2Health News:UCLA Researchers Discover Link Between Parkinsons and Narcolepsy 2Health News:Brickbats And Bouquets For U.S Prison Healthcare In-Charge 2Health News:Brickbats And Bouquets For U.S Prison Healthcare In-Charge 3
Fine angled 12 mm shafts and iris stop. Round handle for fingertip rotational control. Dull finish....
Straight shafts with 4 mm jaws. Serrated handle with dull finish. Jaws angled 45 degrees....
Colibri style with 1.5 mm long angled tip and 0.12 mm teeth. Serrated handles with polished finish....
Double-ended. 12 mm bayonet shaped blade. 10 mm curved blade....
Medicine Products: